Free Trial

Takeda Pharmaceutical (TAK) Competitors

+0.16 (+1.23%)
(As of 01:15 PM ET)


Should you be buying Takeda Pharmaceutical stock or one of its competitors? The main competitors of Takeda Pharmaceutical include Genmab A/S (GMAB), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), and Zoetis (ZTS). These companies are all part of the "pharmaceutical preparations" industry.

Takeda Pharmaceutical vs.

Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

Takeda Pharmaceutical has higher revenue and earnings than Genmab A/S. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$2.39B8.11$631.91M$1.2024.45
Takeda Pharmaceutical$28.20B1.46$994.06M$0.5523.67

Genmab A/S has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Takeda Pharmaceutical has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Genmab A/S presently has a consensus price target of $48.50, suggesting a potential upside of 65.30%. Takeda Pharmaceutical has a consensus price target of $14.00, suggesting a potential upside of 7.53%. Given Takeda Pharmaceutical's higher possible upside, equities research analysts clearly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
3 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
Takeda Pharmaceutical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)

Genmab A/S received 43 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 60.85% of users gave Genmab A/S an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote.

Genmab A/SOutperform Votes
Underperform Votes
Takeda PharmaceuticalOutperform Votes
Underperform Votes

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Genmab A/S had 11 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 13 mentions for Genmab A/S and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.77 beat Genmab A/S's score of 0.39 indicating that Genmab A/S is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
4 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Takeda Pharmaceutical
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)

Genmab A/S has a net margin of 30.74% compared to Genmab A/S's net margin of 6.18%. Takeda Pharmaceutical's return on equity of 18.90% beat Genmab A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Genmab A/S30.74% 18.90% 16.83%
Takeda Pharmaceutical 6.18%9.92%4.71%


Genmab A/S beats Takeda Pharmaceutical on 14 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TAK vs. The Competition

MetricTakeda PharmaceuticalPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$41.21B$6.95B$5.07B$17.70B
Dividend Yield3.96%2.55%2.84%3.44%
P/E Ratio23.6722.72168.0525.71
Price / Sales1.46282.772,526.4410.53
Price / Cash4.0725.6736.5419.39
Price / Book0.825.885.435.88
Net Income$994.06M$146.87M$105.16M$976.87M
7 Day Performance-1.51%-2.04%-1.81%-2.31%
1 Month Performance-1.59%1.66%2.33%2.34%
1 Year Performance-19.88%-7.60%3.26%21.76%

Takeda Pharmaceutical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Genmab A/S
3.0333 of 5 stars
-29.8%$19.27B$17.78B24.292,204News Coverage
Alnylam Pharmaceuticals
4.4956 of 5 stars
Teva Pharmaceutical Industries
0.7608 of 5 stars
3.028 of 5 stars
-34.7%$16.02B$2.46B-22.1110,600Positive News
BioMarin Pharmaceutical
4.9005 of 5 stars
0.6711 of 5 stars
United Therapeutics
4.8732 of 5 stars
+27.9%$12.21B$2.33B13.011,168Analyst Forecast
Insider Selling
Positive News
Sarepta Therapeutics
4.7588 of 5 stars
-13.5%$12.20B$1.24B1,173.821,314Options Volume
Dr. Reddy's Laboratories
1.0514 of 5 stars
4.6955 of 5 stars
-1.0%$78.84B$8.54B33.2914,100Dividend Announcement

Related Companies and Tools

This page (NYSE:TAK) was last updated on 5/24/2024 by Staff

From Our Partners